Risk of Cervical Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Population-Based Studies
Open Access
- 15 June 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 13 (7) , e00513
Abstract
INTRODUCTION: There is increased risk of several malignancies in inflammatory bowel disease (IBD). However, evidence regarding risk of cervical cancer in IBD is conflicting. We aimed to investigate the risk of cervical cancer in IBD by undertaking a systematic review and meta-analysis of unselected, population-based studies. METHODS: MEDLINE, EMBASE, and Cochrane Library were searched using Medical Subject Heading terms, and 2 reviewers independently screened results. Pooled hazard ratios (HRs) were calculated using random effects model meta-analysis for risk of cervical cancer in IBD. Subgroup meta-analysis was undertaken to assess risk of cervical cancer by IBD subtype (Crohn's disease and ulcerative colitis), treatment exposure, and grade of lesion. RESULTS: We screened 1,393 articles to identify 5 population-based studies, including 74,310 patients with IBD and 2,029,087 reference patients, across 5 different countries. Pooled random effects model meta-analysis of these studies did not show statistically significant increased risk for cervical cancer in IBD compared with reference populations (HR: 1.24; 95% confidence interval [CI]: 0.94–1.63). Meta-analysis by grade of lesion showed increased risk of low-grade cervical lesions (HR: 1.15; 95% CI: 1.04–1.28). Meta-analysis by disease subtype indicated no statistically significant increased risk in Crohn's disease (HR: 1.36; 95% CI: 0.83–2.23) or ulcerative colitis (HR: 0.95; 95% CI: 0.72–1.25) or in patients treated with antitumor necrosis factor (HR: 1.19; 95% CI: 0.64–2.21) or thiopurines (HR: 0.96; 95% CI: 0.60–1.50). DISCUSSION: This meta-analysis of high-quality, unselected population-based studies shows no statistically significant increased risk of cervical cancer in patients with IBD. There is, however, increased risk of low-grade cervical lesions compared with the general population.Keywords
This publication has 31 references indexed in Scilit:
- Gastrointestinal Malignancy and the MicrobiomeGastroenterology, 2014
- Immunosuppression and risk of cervical cancerExpert Review of Anticancer Therapy, 2013
- Increased Awareness of the Cervical Cancer Risk and Need for Pap Smears in Women with Inflammatory Bowel Disease Is NecessaryInflammatory Bowel Diseases, 2012
- Effect of autoimmune diseases on risk and survival in female cancersGynecologic Oncology, 2012
- European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary DocumentAnnals of Oncology, 2010
- Lack of association between cervical dysplasia and IBD: A large case–control studyInflammatory Bowel Diseases, 2009
- Suboptimal Rates of Cervical Testing Among Women With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2009
- Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control StudyGastroenterology, 2009
- Cancer in patients with ulcerative colitis, Crohnʼs disease and coeliac disease: record linkage studyEuropean Journal of Gastroenterology & Hepatology, 2008
- Immunity, infection, and cancerThe Lancet, 2007